Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
- 16 October 2015
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 38 (1) , 70-79
Abstract
Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa. Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.Keywords
This publication has 17 references indexed in Scilit:
- Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2012
- Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled TrialClinical Infectious Diseases, 2012
- A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*Critical Care Medicine, 2009
- Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?Critical Care Medicine, 2009
- Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing StrategyClinical Infectious Diseases, 2007
- Population Pharmacokinetics of Continuous Infusion Piperacillin-TazobactamJournal of Infectious Disease Pharmacotherapy, 2002
- CONTINUOUS VS. INTERMITTENT INFUSION OF CEFUROXIME FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIAInfectious Diseases in Clinical Practice, 1998
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to OutcomeClinical Pharmacokinetics, 1995
- CONTINUOUS INFUSION OF CEFTAZIDIME IN CYSTIC FIBROSISThe Lancet, 1989
- THE RATE OF BACTERICIDAL ACTION OF PENICILLIN IN VITRO AS A FUNCTION OF ITS CONCENTRATION, AND ITS PARADOXICALLY REDUCED ACTIVITY AT HIGH CONCENTRATIONS AGAINST CERTAIN ORGANISMSJournal of Experimental Medicine, 1948